ACRS - Aclaris Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.2100
-0.0200 (-0.90%)
At close: 4:00PM EDT

2.2100 0.00 (0.00%)
After hours: 5:04PM EDT

Stock chart is not supported by your current browser
Previous Close2.2300
Open2.2100
Bid2.2200 x 2200
Ask2.2300 x 1200
Day's Range2.1700 - 2.2475
52 Week Range1.9300 - 20.8000
Volume145,955
Avg. Volume753,417
Market Cap91.212M
Beta (3Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-3.9460
Earnings DateMar 14, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 hours ago

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. It was reported on June 20, 2019, that the FDA’s Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” about its risk and efficacy. The FDA letter states that, “a direct-to-consumer video of an interview featuring a paid Aclaris spokesperson” was “especially concerning from a public health perspective because it fails to include information regarding the serious risks associated with Eskata, which bears warnings and precautions related to the risks of serious eye disorders .

  • ACCESSWIRE7 days ago

    Bronstein, Gewirtz & Grossman, LLC Announces Investigation of (ACRS) Aclaris Therapeutics, Inc.

    NEW YORK, NY / ACCESSWIRE / July 10, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ...

  • GlobeNewswire8 days ago

    ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. It was reported on June 20, 2019, that the FDA’s Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” about its risk and efficacy. The FDA letter states that, “a direct-to-consumer video of an interview featuring a paid Aclaris spokesperson” was “especially concerning from a public health perspective because it fails to include information regarding the serious risks associated with Eskata, which bears warnings and precautions related to the risks of serious eye disorders .

  • Benzinga8 days ago

    Aclaris Shares Trade Higher On Patent Win For Facial Redness Drug

    Aclaris Therapeutics Inc (NASDAQ: ACRS ) shares were seeing some upward momentum Tuesday on the back of the announcement of a patent win. What Happened The U.S. Patent and Trademark Office has granted ...

  • What Makes Aclaris (ACRS) a New Buy Stock
    Zacks8 days ago

    What Makes Aclaris (ACRS) a New Buy Stock

    Aclaris (ACRS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire8 days ago

    Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1%

    Issuance of U.S. Patent No. 10,335,391 Further Strengthens Aclaris’ RHOFADE Patent Portfolio WAYNE, Pa., July 09, 2019 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a.

  • GlobeNewswire9 days ago

    Bragar Eagel & Squire, P.C. Reminds Investors of Its Investigations of Pintec, Sealed Air, and Aclaris Therapeutics on Behalf of Stockholders and Encourages Investors to Contact the Firm

    NEW YORK, July 07, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Pintec Technology Holdings, Ltd., Sealed Air Corporation, and Aclaris.

  • Here’s What Hedge Funds Think About Aclaris Therapeutics, Inc. (ACRS)
    Insider Monkey12 days ago

    Here’s What Hedge Funds Think About Aclaris Therapeutics, Inc. (ACRS)

    "Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

  • GlobeNewswire14 days ago

    Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors

    Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board of directors, effective July 2, 2019. Dr. Gowen founded Trevena, Inc. and served as its President and Chief Executive Officer from 2007 until October 2018. Prior to this, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years.

  • GlobeNewswire15 days ago

    ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. It was reported on June 20, 2019, that the FDA’s Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” about its risk and efficacy. The FDA letter states that, “a direct-to-consumer video of an interview featuring a paid Aclaris spokesperson” was “especially concerning from a public health perspective because it fails to include information regarding the serious risks associated with Eskata, which bears warnings and precautions related to the risks of serious eye disorders .

  • ACCESSWIRE17 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

    NEW YORK, NY / ACCESSWIRE / June 30, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (ACRS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Aclaris and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • ACCESSWIRE19 days ago

    INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / June 28, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or "the Company") (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. It was reported on June 20, 2019, that the FDA's Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris's hydrogen peroxide topical solution, Eskata, "makes false or misleading claims" about its risk and efficacy.

  • ACCESSWIRE19 days ago

    SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / June 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or "the Company") (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. It was reported on June 20, 2019, that the FDA's Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris's hydrogen peroxide topical solution, Eskata, "makes false or misleading claims" about its risk and efficacy.

  • Here's Why Aclaris Therapeutics Stock Collapsed Today
    Motley Fool20 days ago

    Here's Why Aclaris Therapeutics Stock Collapsed Today

    A mid-stage trial failure has investors questioning the company's approach.

  • GlobeNewswire20 days ago

    Bragar Eagel & Squire, P.C. Reminds Investors of Its Investigations of Aclaris Therapeutics, electroCore, Pintec, and Sealed Air on Behalf of Stockholders and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. is investigating potential claims against Aclaris Therapeutics, Inc., electroCore, Inc., Pintec Technology Holdings, Ltd., and Sealed Air Corporation on behalf of Investors. On June 20, 2019, the U.S. Food & Drug Administration (“FDA”) stated that an advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” regarding the product’s risk and efficacy. If you purchased or otherwise acquired Aclaris shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.

  • Business Wire20 days ago

    Glancy Prongay & Murray LLP Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

    Glancy Prongay & Murray LLP (“GPM”) announces the continuation of its investigation on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On June 20, 2019, the U.S. Food & Drug Administration (“FDA”) stated that an advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” regarding the product’s risk and efficacy.

  • Business Wire21 days ago

    INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

    Law Offices of Howard G. Smith announces the continuation of its investigation on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) investors concerning the Company and its officers’ possible violations of federal securities laws. On June 20, 2019, the U.S. Food & Drug Administration (“FDA”) stated that an advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” regarding the product’s risk and efficacy.

  • ACCESSWIRE21 days ago

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / June 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or "the Company") (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. It was reported on June 20, 2019, that the FDA's Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris's hydrogen peroxide topical solution, Eskata, "makes false or misleading claims" about its risk and efficacy.

  • GlobeNewswire21 days ago

    Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints

    Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced results from a Phase 2 clinical trial of ATI-502 (AA-201 Topical), an investigational topical Janus Kinase (JAK) 1/3 inhibitor, in patients with alopecia areata (AA). ATI-502 did not achieve statistical superiority at the primary or secondary endpoints due to high rates of disease resolution in vehicle-treated patients. The primary endpoint was the mean percent change from baseline in the Severity of Alopecia Tool (SALT) score at week 24.  Secondary endpoints included change in Alopecia Density and Extent (ALODEX) score and multiple investigator and patient reported outcomes.

  • FDA asks Chester County biopharm company to pull promotional video
    American City Business Journals21 days ago

    FDA asks Chester County biopharm company to pull promotional video

    The federal agenecy claims the video has misleading and incomplete information about the company's skin disorder treatment.

  • Business Wire23 days ago

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

    Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On June 20, 2019, the U.S. Food & Drug Administration (“FDA”) stated that an advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” regarding the product’s risk and efficacy.

  • Business Wire23 days ago

    INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. It was reported on June 20, 2019, that the FDA’s Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” about its risk and efficacy.

  • Business Wire23 days ago

    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

    Law Offices of Howard G. Smith announces an investigation on behalf of Aclaris Therapeutics, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.